Abstract: A non-invasive blood gas test is carried out by a method that utilizes a venous blood sample together with a pulse oximeter and a plurality of mathematical equations. The method generates the following data points of the blood: (i) the pH level; (ii) the [H+] concentration; (iii) the [HCO3—] concentration; (iv) the partial pressure of carbon dioxide; and (v) the oxygen saturation level. Mathematical formulas, tables, and chemical equations provide a simple method by which a doctor or other medical professional can easily calculate the blood gas data without the need for an arterial blood sample or specialized machines. Blood gas measurements are obtained from a patient in a faster, safer and less painful manner than tests that require an arterial blood sample. In another embodiment of the present invention, a system for locating a dysfunctional organ in a patient is disclosed.

Abstract: A non-invasive blood gas test is carried out by a method that utilizes a venous blood sample together with a pulse oximeter and a plurality of mathematical equations. The method generates the following data points of the blood: (i) the pH level; (ii) the [H+] concentration; (iii) the [HCO3—] concentration; (iv) the partial pressure of carbon dioxide; and (v) the oxygen saturation level. Mathematical formulas, tables, and chemical equations provide a simple method by which a doctor or other medical professional can easily calculate the blood gas data without the need for an arterial blood sample or specialized machines. Blood gas measurements are obtained from a patient in a faster, safer and less painful manner than tests that require an arterial blood sample. In another embodiment of the present invention, a system for locating a dysfunctional organ in a patient is disclosed.

Abstract: Acute and chronic heart disease is treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The progress of treatment is continuously monitored by echo-cardiogram with growth factor treatment and/or stem cell administration adjusted according to the results of the echo-cardiogram or clinical status of the patient. Heart disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Abstract: Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Abstract: Acute and chronic diseases of the organs are treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells or other cell therapy. The patient can be a fetus treated in utero or removed from the womb. The progress of treatment is monitored by ultrasound, MRI, CAT scan, cardiac echo, EEG, EKG, EMG or blood tests, with growth factor treatment and/or stem cell administration adjusted according to the results of the monitoring or clinical status of the patient. Organ disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation or intranasal therapy. Diseases affecting organs such as the brain, spinal cord, pancreas, liver, kidney, muscle, heart and upper and lower gastrointestinal tracts are treated using the present method. A device for treatment is disclosed. CPK is utilized to assess the treatment of muscle disease.

Abstract: Acute and chronic diseases of the organs are treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The patient can be a fetus treated in utero or removed from the womb. The progress of treatment is continuously monitored by ultrasound, MRI, CAT scan, cardiac echo, EEG, EKG, EMG or blood tests, with growth factor treatment and/or stem cell administration adjusted according to the results of the monitoring or clinical status of the patient. Organ disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation or intranasal therapy. Diseases affecting organs such as the brain, spinal cord, pancreas, liver, kidney, muscle, and upper and lower gastrointestinal tracts are treated using the present method. A device for treatment is disclosed. CPK is utilized to assess the treatment of muscle disease.

Abstract: Stem cells are mobilized into the peripheral blood by a method comprising the steps of: (i) administering to an individual at least one of the following: FGF1 and FGF2, and also at least one of the following: VEGF, VEGFA, VEGFB, PLGF, VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206; (ii) isolating the peripheral blood stem cells (PBSC) by apheresis; and (iii) treating a patient suffering from organ disease with PBSC. Alternatively, gene therapy is used for the induction of the stem cells into the peripheral blood, wherein the gene therapy formulation comprises AD5FGF-4 or VEGF165 plasmid DNA. Additionally, the progress of the treatment of the organ disease is monitored by using an ultrasound unit.

Abstract: Acute and chronic heart disease is treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The progress of treatment is continuously monitored by echo-cardiogram with growth factor treatment and/or stem cell administration adjusted according to the results of the echo-cardiogram or clinical status of the patient. Heart disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Abstract: Stem cells are mobilized into the peripheral blood by a method comprising the steps of: (i) administering to an individual at least one of the following: FGF1 and FGF2, and also at least one of the following: VEGF, VEGFA and VEGF165; (ii) isolating the peripheral blood stem cells (PBSC) by apheresis; and (iii) injecting the PBSC into a patient suffering from chronic heart disease. Alternatively, gene therapy is used for the induction of the stem cells into the peripheral blood, wherein the gene therapy formulation comprises AD5FGF-4 or VEGF165 plasmid DNA. Additionally, the progress of the treatment of the chronic heart disease is monitored by using an echocardiogram unit.